NCT04914390View on ClinicalTrials.gov

A Phase Ⅱ Study of Anlotinib Combined With Tislelizumab and AT in the Neoadjuvant Treatment of Triple-negative Breast Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

September 15, 2023

Primary Completion Date

March 31, 2025

Study Completion Date

September 30, 2025

Conditions
Triple-negative Breast Cancer
Interventions
DRUG

AT regimen

Doxorubin 60mg/㎡ d1 or Epirubicin 75mg/㎡ d1 and Nab-paclitaxel 260mg/㎡ d1 of Cycles 1-6 (Q3W) of the neoadjuvant phase of the study; IV injection.

DRUG

Tislelizumab

200mg on d1 of Cycles 1-6 (Q3W) of the neoadjuvant phase of the study; IV injection.

DRUG

Anlotinib

8mg on d1-14 of Cycles 1-5 (Q3W) of the neoadjuvant phase of the study; po. Arotinib is a small molecule multi-target TKI, which exerts its effect by inhibiting angiogenesis, a critical component of tumour growth and metastasis.

Trial Locations (1)

610031

RECRUITING

Department of breast surgery, Sichuan Provincial People's Hospital, Chengdu

All Listed Sponsors
lead

Sichuan Provincial People's Hospital

OTHER